Post-Operative Pain - Pipeline Review, H2 2020

July 2020 | 302 pages | ID: PB52535144BEN
Global Markets Direct

Abstracts

Post-Operative Pain - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain - Pipeline Review, H2 2020, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.
Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 1, 5, 21, 18, 4, 33, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Unknown stages comprises 1, 3 and 1 molecules, respectively.
Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Post-Operative Pain - Overview
Post-Operative Pain - Therapeutics Development
Post-Operative Pain - Therapeutics Assessment
Post-Operative Pain - Companies Involved in Therapeutics Development
Post-Operative Pain - Drug Profiles
Post-Operative Pain - Dormant Projects
Post-Operative Pain - Discontinued Products
Post-Operative Pain - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Post-Operative Pain, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc, H2 2020
Post-Operative Pain - Pipeline by Adare Pharmaceuticals Inc, H2 2020
Post-Operative Pain - Pipeline by Adynxx Inc, H2 2020
Post-Operative Pain - Pipeline by Algomedix Inc, H2 2020
Post-Operative Pain - Pipeline by Altus Formulation Inc, H2 2020
Post-Operative Pain - Pipeline by AmacaThera Inc, H2 2020
Post-Operative Pain - Pipeline by Andros Pharmaceuticals Co Ltd, H2 2020
Post-Operative Pain - Pipeline by AngioChem Inc, H2 2020
Post-Operative Pain - Pipeline by Antibe Therapeutics Inc, H2 2020
Post-Operative Pain - Pipeline by Bayer AG, H2 2020
Post-Operative Pain - Pipeline by Benuvia Therapeutics Inc, H2 2020
Post-Operative Pain - Pipeline by Cadila Healthcare Ltd, H2 2020
Post-Operative Pain - Pipeline by Cali Pharmaceuticals LLC, H2 2020
Post-Operative Pain - Pipeline by Camurus AB, H2 2020
Post-Operative Pain - Pipeline by Cara Therapeutics Inc, H2 2020
Post-Operative Pain - Pipeline by Cellix Bio Pvt Ltd, H2 2020
Post-Operative Pain - Pipeline by CerSci Therapeutics Inc, H2 2020
Post-Operative Pain - Pipeline by Chromocell Corp, H2 2020
Post-Operative Pain - Pipeline by Concentric Analgesics Inc, H2 2020
Post-Operative Pain - Pipeline by Cytogel Pharma LLC, H2 2020
Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA, H2 2020
Post-Operative Pain - Pipeline by Douleur Therapeutics Inc, H2 2020
Post-Operative Pain - Dormant Projects, H2 2020
Post-Operative Pain - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Post-Operative Pain, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

AcelRx Pharmaceuticals Inc
Adare Pharmaceuticals Inc
Adynxx Inc
Algomedix Inc
Altus Formulation Inc
AmacaThera Inc
Andros Pharmaceuticals Co Ltd
AngioChem Inc
Antibe Therapeutics Inc
Bayer AG
Benuvia Therapeutics Inc
Cadila Healthcare Ltd
Cali Pharmaceuticals LLC
Camurus AB
Cara Therapeutics Inc
Cellix Bio Pvt Ltd
CerSci Therapeutics Inc
Chromocell Corp
Concentric Analgesics Inc
Cytogel Pharma LLC
Dompe Farmaceutici SpA
Douleur Therapeutics Inc
DURECT Corp
Esteve Pharmaceuticals SA
Euclises Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc
Flexion Therapeutics Inc
Fujimoto Pharmaceutical Corp
Grunenthal GmbH
H. Lundbeck AS
Hana Pharm Co Ltd
Heron Therapeutics Inc
Innocoll AG
InSitu Biologics LLC
Insys Therapeutics Inc
Ionis Pharmaceuticals Inc
iX Biopharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Liquidia Technologies Inc
Lumosa Therapeutics Co Ltd
Luye Pharma Group Ltd
Medical Developments International Ltd
MedinCell SA
Mundipharma International Ltd
Neokera LLC
Neumentum Inc
NeurAxon Pharma Inc
NeuroPn Therapeutics LLC
Ocular Therapeutix Inc
Pacira BioSciences Inc
PainReform Ltd
Pharmaleads SA
Pharmazz Inc
PhytoHealth Corp
PolyPid Ltd
Quoin Pharmaceuticals Ltd
Revogenex Inc
RHNanopharmacuticals LLC
Rottapharm Biotech Srl
Sedor Pharmaceuticals LLC
Seelos Therapeutics, Inc.
Serina Therapeutics Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SiteOne Therapeutics Inc
Sotex Pharm Firm
SteadyMed Therapeutics Inc
Taiwan Liposome Co Ltd
Teikoku Pharma USA Inc
Theracaine LLC
Trevena Inc
Vertex Pharmaceuticals Inc
Virpax Pharmaceuticals Inc
Vivozon Inc
Xgene Pharmaceutical Inc
Xigen SA
Yichang Humanwell Pharmaceutical Co Ltd